Pfizer Developing Third Covid Shot To ‘Target The Delta Variant’

NEW YORK, NY – JANUARY 17: Albert Bourla, chief executive officer of Pfizer pharmaceutical company, waits to ring the closing bell at the New York Stock Exchange (NYSE) on Thursday afternoon, January 17, 2019 in New York City. The Dow Jones Industrial Average was up over 150 points at the close on Thursday, after news reports that Treasury Secretary Steven Mnuchin is floating a proposal to lift some U.S. tariffs on Chinese goods in an effort to push trade talks forward between the U.S. and China. (Photo by Drew Angerer/Getty Images)

On Thursday Pfizer and BioNTech announced the development of a Covid-19 booster shot intended to target the Delta Variant, which was first identified in India.

According to the companies, the two-dose vaccine declines in efficacy over time, thus providing the need for a third booster shot in order to combat new strains such as the much less deadly Delta variant.

“As seen in real world evidence released from the Israel Ministry of Health, vaccine efficacy has declined six months post-vaccination, at the same time that the Delta variant is becoming the dominate variant in the country,” the companies said in a written statement.

“These findings are consistent with an ongoing analysis from the companies’ Phase 3 study,” they said. “That is why we have said, and we continue to believe that it is likely, based on the totality of the data we have to date, that a third dose may be needed within 6 to 12 months after full vaccination.”

The companies reportedly said that clinical studies could begin as early as August.

The announcement comes the same day the Olympics announced the banning of all spectators this year after Japan declared a state of emergency due to a wave of new COVID-19 infections.

Executives from Pfizer and BioNtech have repeatedly said people will likely need a booster shot, or third dose, within 12 months of receiving both shots because they expect vaccine-induced immunity to wane over time. They also claim that it is likely people will need to get additional shots each year.

Both companies plan on seeking U.S. authorization for the third dose of the vaccine shortly.

Various large pharmaceutical companies like Pfizer, BioNTech, Moderna, and Johnson & Johnson continue to incur massive profits from mass vaccination around the United States, raking in numerous multi-billion dollar deals. It goes without saying that both companies also benefit financially from forced vaccination, a phenomenon that has recently affected many Americans nationwide with the COVID-19 shot.